Wagner Paul A. 4
4 · Forte Biosciences, Inc. · Filed Jan 2, 2025
Insider Transaction Report
Form 4
Wagner Paul A.
DirectorSEE REMARKS
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-01-01−1,250→ 10,000 total→ Common Stock (1,250 underlying) - Exercise/Conversion
Common Stock
2025-01-01+1,250→ 78,720 total - Tax Payment
Common Stock
2025-01-01$22.71/sh−164$3,724→ 78,556 total
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
- [F2]On January 1, 2025, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2024 was the settlement price used to calculate the shares withheld.
- [F3]Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.